Give the same GLP-1 to a room of people and the results scatter wildly. In clinical trials, a third or more lose over 20% of their body weight — but the real world is more sobering: a large analysis of more than 135,000 patients found only about 1 in 8 lost more than 15% in a year, while nearly half lost less than 5%. Same drugs, radically different outcomes. Those two ends have names — super-responders and non-responders — and a fair amount is now known about what separates them. Here's what the evidence says, and what it means whether you're losing fast, slow, or barely at all.
What "super-responder" actually means
There's no official medical definition, but researchers draw the lines by how much total body weight someone loses over about a year: super-responders lose more than roughly 15–20%, non-responders lose less than 5%, and most people land in between.
How common each is depends heavily on whether you're looking at a trial or real life. In a large real-world analysis of 135,349 GLP-1 users, the breakdown was: 12.5% super-responders (>15% loss), 35.2% moderate (5–15%), 46.8% minimal (<5%), and a small group who regained (Venkatakrishnan et al., Biology Methods and Protocols, 2026, DOI (external link), via PubMed). That's markedly less impressive than the clinical trials, where roughly a third or more reach 20%+ — and the gap is the important part: much of it comes down to real-world adherence, discontinuation, and never reaching an effective dose, not biology alone.
What predicts a strong response
Several factors tilt the odds, though none guarantees an outcome:
- A fast early response. Super-responders often notice the effect almost immediately — "food noise" and cravings quieting within days, sometimes hours, of the first dose — and that early drop tends to foreshadow a bigger overall result.
- Which drug. The dual-hormone drug tirzepatide (Mounjaro, Zepbound) produces super-response more often than (Ozempic, Wegovy). In that real-world analysis the super-responder rate was highest for Zepbound (34%) and lowest for Ozempic (10%), and head-to-head the odds of super-response strongly favored tirzepatide — versus at an odds ratio of , and versus at (Venkatakrishnan et al., , 2026, , via PubMed).